Shanghai Jemincare Pharmaceuticals Co., Ltd.

Jiangxi Jemincare Group Co., Ltd.

Genentech, Inc.

Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Yangtze River Pharmaceutical Group Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Jianbiao Peng

Haibing Guo

Weiqiang Xing

Hongfu Lu

Yang Liu

Shuchun Guo

Baojian Qi

Jiong Lan

Yongcong Lv

Qing Dong

Hui Li

Piaoyang Sun

Qiong Zhang

Qiyue Hu

Guoqing Cao

Jun Fan

Fangfang Jin

Xiaotao Li

Fang Bao

Bonian Liu

Jiangwei Wang

Chunyan Gu

Lixiao Wang

Chunzhou Han

Shan Yao

Zhihua Fang

Zhangping Kang

Zonglei Fei

Yan Ye

Yong Zhang

Provided are a protein degradation agent compound preparation method and application; specifically, provided are the compound represented by formula (I) and a pharmacologically acceptable salt thereof, and an application of said compound in the degradation of androgen receptor (AR).

Protein degradation agent compound preparation method and application

Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.

Phthalazinone compound, and preparation method therefor and medical use thereof

Relating to a compound represented by formula (I) and a pharmaceutically acceptable salt of the compound, and an application of the compound as an S1P1 agonist.

Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative

Disclosed in the present invention are a fused pyridone compound, and a preparation method therefor and a use thereof. Specifically, the present invention discloses a compound of formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor.

Fused pyridone compound, and preparation method therefor and use thereof

A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor. 

Tricyclic compound, preparation method therefor and use thereof

Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compound acting as a STING agonist. 

Cyclic dinucleotide compound and uses thereof

Provided are 4,5,6-tri-substituted indazoles derivatives, a preparation method therefor, and a use thereof in medicines. Specifically, provided are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates, or prodrugs thereof, a preparation method therefor, and a use thereof. 

4,5,6-trisubstituted indazole derivatives, and preparation method and pharmaceutical use thereof

Cycloalkyl acid derivatives, a preparation method thereof, and a pharmaceutical application thereof are described. In particular, a cycloalkyl acid derivative represented by general formula (I) and a medical salt thereof, a preparation method thereof, and an application of the cycloalkyl acid derivative and the medical salt thereof as URAT1 inhibitors, and particularly as therapeutic agents for diseases related to an abnormal uric acid level are described, wherein definitions of substituent groups in general formula (I) are the same as the definitions in the specification. 

Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof

Growing community of inventors

Shanghai, China

Jianbiao Peng